Pharmacokinetics of Ketamine in Infants and Children
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Dosing of medications is based on the plasma level achieved with a given dose and how long the medicine remains in the body. This study is called pharmacokinetics-that is, what the body does to the medication. Ketamine is an intravenous medication used for anesthesia and sedation in children. However the pharmacokinetics of Ketamine has not been systematically studied. We propose to study the pharmacokinetics of ketamine in different age groups of children ranging from infants to teenagers.
| Condition | Intervention |
|---|---|
|
General Anesthesia Sedation Pain Management |
Drug: ketamine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Pharmacokinetics of Ketamine in Infants and Children |
- Age-dependent pharmacokinetic parameters [ Time Frame: 5-720 minutes ]
| Estimated Enrollment: | 50 |
| Study Start Date: | July 2007 |
| Estimated Study Completion Date: | January 2009 |
-
Drug: ketamine hydrochloride
This is an open label study that will be conducted in infants and children presenting for procedures (eg., surgery or cardiac catheterization) at Stanford and Lucile Packard Children's hospital in California and at The Children's Hospital in Denver, CO. Patients with abnormal kidney or liver functions will be excluded from the study as the dysfunction in these organs affects the clearance of medications from the body and affects dosing. Preterm neonates will also be excluded. All patients will be premedicated and anesthetised at the discretion of the anesthesia faculty providing clinical care for the child. Once the patient's procedure is underway, a 0.5 cc blood sample will be drawn from an intravenous line. This is the preload blood sample (T0). Following this a 2mg/kg intravenous bolus of Ketamine will be administered over 5 minutes (this is the usual dose and manner in which ketamine is administered). Five minutes after the bolus, timed blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus. (Total 14 blood samples; total blood required is 7 mls for the entire study). When the procedure is completed the anesthesiologist will awaken the patient as per their usual practice. Blood samples that still need drawing will be done in the post-anesthesia recovery room or intensive care or ward-any location where the patient is likely to remain after the surgery.
Eligibility| Ages Eligible for Study: | up to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Term infants (38 weeks gestation)and infants and children up to age 18 years.
- Patients who require procedures that necessitate at least 8 hours in the hospital and those being admitted after procedure will be eligible to participate.
- Patients who will receive ketamine as part of their standard anesthesia regimen.
Exclusion Criteria:
- Preterm neonates
- Liver Disease
- Kidney disease
- Heart failure
- Sepsis
- Patients receiving anticonvulsants or barbiturates
Contacts and Locations| Contact: Chandra Ramamoorthy, MBBS, FRCA | 650-724-7093 | chandrar@stanford.edu |
| Contact: Nancy Federspiel, PhD | 650-725-7512 | nfeder@stanford.edu |
| United States, California | |
| Lucile Packard Children's Hospital | Recruiting |
| Palo Alto, California, United States, 94304 | |
| Contact: Chandra Ramamoorthy, MBBS, FRCA 650-724-7093 chandrar@stanford.edu | |
| Contact: Nancy A Federspiel, PhD 650-725-7512 nfeder@stanford.edu | |
| Principal Investigator: Chandra Ramamoorthy, MBBS, FRCA | |
| United States, Colorado | |
| The Children's Hospital | Recruiting |
| Denver, Colorado, United States, 80218 | |
| Contact: Jeffrey L Galinkin, MD 303-869-3399 jeffrey.galinkin@uchsc.edu | |
| Contact: Jeannie Zuk zuk.jeannie@tchden.org | |
| Principal Investigator: Jeffrey L. Galinkin, MD | |
| Principal Investigator: | Chandra Ramamoorthy, MBBS, FRCA | Stanford University |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00553839 History of Changes |
| Other Study ID Numbers: | 3384 |
| Study First Received: | November 5, 2007 |
| Last Updated: | November 5, 2007 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Stanford University:
|
ketamine pharmacokinetics neonates |
infants children pediatric |
Additional relevant MeSH terms:
|
Ketamine Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents |
Therapeutic Uses Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on May 21, 2013